WASHINGTONThe FDA has approved Orphan Medicals Busulfex (busulfan) Injection for use in combination with cyclophosphamide(Drug information on cyclophosphamide) as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). (See Oncology News International, February 1999, for a report on the Oncology Drugs Advisory Committees discussion of the agent and its recommendation to the FDA.)
